Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term

Baudouin, Christophe; Hamard, P.; Liang, Hong; Creuzot‐Garcher, Catherine; Bensoussan, L.; Brignole, F.

doi:10.1016/j.ophtha.2004.06.023

Cited by 178 publications

(122 citation statements)

References 39 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…However, several investigators have suggested that the prolonged medical treatment may prejudice the success of surgical treatment priming the conjunctival cellular population for an excessive response to surgical wounding. Prolonged medical treatment has been reported to stimulate increased conjunctival cell expression of the inflammatory cell marker HLA-DR. 14, 15 Sherwood et al 16 (using toluidine blue staining and cell morphology techniques) reported a significant increase in macrophages, lymphocytes, mast cells, and fibroblasts in the group of glaucoma patients who had received more than two types of drops for at least 1 year compared with glaucoma patients who underwent filtration surgery as a primary treatment. Broadway et al 17 reported that glaucoma patients who had received multiple topical treatments have a lower success rate after filtration surgery compared with those who undergo primary trabeculectomy.…”

mentioning

confidence: 99%

Increased mast cell numbers in the conjunctiva of glaucoma patients: a possible indicator of preoperative glaucoma surgery inflammation

Chang

Wong

Ohbayashi³

et al. 2008

Eye

View full text Add to dashboard Cite

mentioning

confidence: 99%

Increased mast cell numbers in the conjunctiva of glaucoma patients: a possible indicator of preoperative glaucoma surgery inflammation

Chang

Wong

Ohbayashi³

et al. 2008

Eye

View full text Add to dashboard Cite

“…С помощью импрессионной цитологии и про-точной цитометрии удалось выяснить, что при гла-укоме в эпителии идёт активная гиперэкспрессия антигенов HLA-DR класса II, ICAM-1 и интер-лейкинов ИЛ-6, ИЛ-8 и ИЛ-10, хотя клинической симптоматики она не даёт [12,14,35]. На фоне инстилляций капель, содержащих консерванты, и нескольких видов препаратов повышается уро-вень экспрессии маркеров воспаления и цитоки-нов.…”

Section: The Influence Of Local Iop-lowering Therapy On the Anterior unclassified

The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Petrov

Юрьевич²,

Lovpache

et al. 2017

Ophthalmology Reports

View full text Add to dashboard Cite

Nowadays, a wide choice of local IOP-lowering medications allows ensuring a successful intraocular pressure compensation and primary open angle glaucoma stabilization. However, taking into consideration a long term action of drugs on the ocular surface, even without clinical manifestations there is a direct inflammatory cells’ activation with mixed toxic and allergic changes, which is confirmed by histology, immune-histology, and impression cytology methods. Such chronic sub-clinical inflammation represent a potential risk of excessive fibroblast proliferation with subsequent rapid postoperative scarring of new outflow pathways and atypical filtration bleb formation. It is shown that there is a clear relationship between number of glaucoma drugs used, treatment duration, intensity of conjunctival infiltration with inflammatory cells and fibroblasts, and risk of episcleral fibrosis and subconjunctival scarring during post-op period. (For citation: Petrov SYu, Lovpache DzhN, Loskutov IA, Safronova DM. The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery. Ophthalmology Journal. 2017;10(4):41-47. doi: 10.17816/OV10441-47).

show abstract

“…Patients with glaucoma are generally older and may have cardiac or pulmonary disease, which may be worsened following the use of β-blockers (7). In addition, ocular side-effects that occur with the use of β-blockers include burning, stinging and dry eyes, and are generally associated with preservatives in the drug solution (16,17). ii) Cholinergic drugs, including pilocarpine, which is most frequently administered and a natural parasympathomimetic alkaloid.…”

Section: Current Treatments For Glaucomamentioning

confidence: 99%

Targeting the A3 adenosine receptor for glaucoma treatment (Review)

Fishman

Cohen

Bar-Yehuda

2013

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Glaucoma is a worldwide disease and the second leading cause of blindness. Current treatments are associated with a number of side-effects and poor compliance, due to the requirement for treatment administration several times a day. These treatments typically aim to lower intraocular pressure (IOP); however, they are unable to protect retinal ganglion cells (RGCs) from undergoing apoptosis, which is the main cause of vision loss. A 3 adenosine receptor (A 3 AR) agonists have been found to protect normal cells from undergoing apoptosis via the downregulation of death signals. Furthermore, A 3 AR agonists have been reported to have several ophthalmological effects, including the prevention of ganglion cell apoptosis in vitro and in vivo and anti-inflammatory effects in experimental models of autoimmune uveitis. CF101, an orally bioavailable A 3 AR agonist, has been analyzed in dry eye syndrome phase II clinical trials and was identified to be safe and well tolerated. The anti-inflammatory effect of CF101 was shown to significantly improve corneal staining, tear meniscus and tear break-up time in dry eye patients. In addition, CF101 was found to decrease IOP in patients. The safety and efficacy of CF101, together with its suitability for oral administration, indicates that it has potential as a candidate drug for the treatment of glaucoma.

show abstract

Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term

Cited by 178 publications

References 39 publications

Increased mast cell numbers in the conjunctiva of glaucoma patients: a possible indicator of preoperative glaucoma surgery inflammation

Increased mast cell numbers in the conjunctiva of glaucoma patients: a possible indicator of preoperative glaucoma surgery inflammation

The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Targeting the A3 adenosine receptor for glaucoma treatment (Review)

Contact Info

Product

Resources

About